FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
X

Find Approved Drugs for Genetic Disease in Clinical Development

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Recombinant coagulation factor IX

            Therapeutic Area: Genetic Disease

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Medexus Pharmaceuticals

            Deal Size: $30.0 million Upfront Cash: $30.0 million

            Deal Type: Acquisition February 28, 2020

            Details:

            Acquisition strengthens Medexus’ specialty product portfolio and represents a strategic fit with other products in the Medexus business development pipeline.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Koate DVI

            Therapeutic Area: Genetic Disease

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: WuXi Biologics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition January 16, 2020

            Details:

            First drug product facility in Europe to complement WuXi Biologics’ existing commercial manufacturing capacities. WuXi Biologics will be the back-up manufacturer for Kovaltry™ of Bayer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Deferiprone

            Therapeutic Area: Genetic Disease

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Chiesi Group

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition January 13, 2020

            Details:

            Chiesi Group expands distribution network via acquisition for worldwide product rights.